Published on 13 Mar 2024 on Zacks via Yahoo Finance
NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up
NewAmsterdam Pharma Company N.V. NAMS announced the dosing of the first patient and the initiation of the late-stage study TANDEM.
This phase III placebo-controlled, double-blind, four-arm, randomized study is designed to evaluate obicetrapib and ezetimibe fixed-dose combination (FDC) as an adjunct to diet and maximally tolerated lipid lowering therapy in patients with Heterozygous Familial Hypercholesterolemia (HeFH), Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD risk equivalents requiring an additional lowering of low-density lipoprotein cholesterol (LDL-C).
Shares of this late-stage biopharmaceutical company have risen 11.9% on the news.